Q2 2026 Abeona Therapeutics Inc Earnings Call Transcript
Key Points
- Abeona Therapeutics Inc (ABEO) reported a 31% quarter-over-quarter increase in ZEVASKYN net revenue, reaching $11.4 million in Q2 2026.
- The company expanded its qualified treatment center (QTC) network to seven activated centers, including major institutions like Cincinnati Children's, CHOP, and New York-Presbyterian, improving patient access.
- ZEVASKYN received CMS New Technology Add-on Payment (NTAP) status for fiscal year 2027, which provides supplemental reimbursement for hospitals and is expected to facilitate patient access and payer negotiations.
- Manufacturing yields have improved in commercial settings, averaging nine sheets per lot compared to about five in clinical trials, indicating better production efficiency.
- The company maintains a strong balance sheet with $146.8 million in cash and short-term investments, supporting its path toward a sustainable cash flow positive business model.
- Abeona Therapeutics Inc (ABEO) experienced manufacturing challenges, including a low-yield batch in Q2 and an out-of-specification batch in Q3, leading to no revenue recognition for two treated patients.
- Patient health deterioration caused two last-minute biopsy cancellations in Q2, disrupting treatment schedules and highlighting the unpredictability of patient flow.
- The time from patient identification to treatment varies significantly across QTCs, with some sites taking over 12 months to treat their first patient, indicating operational bottlenecks.
- The company's gross margin was only 63% in Q2, and normalized margins are expected to be 85-90% only at full capacity, which may not be achieved soon.
- The company has revised its reporting to focus only on completed treatments and revenue, reducing transparency on the patient funnel and leading indicators, which may limit investor visibility.
Good morning, everyone, and welcome to Abeona Therapeutics 2Q 2026 conference call. (Operator Instructions) Please note this conference is being recorded.
I will now turn the conference over to your host, Gregory Gin, Vice President, Investor Relations and Corporate Development. Greg, the floor is yours.
Thank you, Jenny. Good morning, and thank you, everyone, for joining us on our second quarter 2026 results conference call. During this call, we will refer to the press release issued this morning announcing the financial results. It's available on our corporate website at www.abeonatherapeutics.com.
Joining me on today's call are Dr. Vish Seshadri, Chief Executive Officer; Dr. Madhav Vasanthavada, Chief Commercial Officer; Joe Vazzano, Chief Financial Officer; and Dr. Brian Kevany, Chief Technical Officer. We anticipate making projections and forward-looking statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
